The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

Detalhes bibliográficos
Autor(a) principal: Harmatz, Paul
Data de Publicação: 2013
Outros Autores: Mengel, Karl Eugen, Giugliani, Roberto, Valayannopoulos, Vassili, Lin, Shuan-Pei, Parini, Rossella, Guffon, Nathalie, Burton, Barbara K., Hendriksz, Christian J., Mitchell, John, Martins, Ana Maria [UNIFESP], Jones, Simon, Guelbert, Norberto, Vellodi, Ashok, Hollak, Carla, Slasor, Peter, Decker, Celeste
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1016/j.ymgme.2013.01.021
http://repositorio.unifesp.br/handle/11600/36233
Resumo: Objectives: the objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects.Methods: MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels.Results: Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean +/- SD height z-scores were -5.6 +/- 3.1 as determined by the CDC growth charts. Mean +/- SD from the 6-minute-walk-test was 212.6 +/- 1522 m, revealing limitations in functional endurance testing, and 30.0 +/- 24.0 stairs/min for the 3-minute-stair-climb test. Respiratory function showed limitations comparable to MPS VI patients; mean +/- SD was 1.2 +/- 0.9 1 based on forced vital capacity and 34.8 +/- 25.5 l/min based on maximum voluntary ventilation. Mean urinary keratan sulfate (uKS) was elevated for all ages, and negatively correlated with age. Higher uKS correlated with greater clinical impairment based on height z-scores, endurance and respiratory function tests. the MPS Health Assessment Questionnaire reveals impairments in mobility and activities of daily living in comparison to an age-matched control population.Conclusions: MPS IVA is a multisystem disorder with a continuum of clinical presentation. All affected individuals experience significant functional limitations and reduced quality of life. Older patients have more severe exercise and respiratory capacity limitations, and more frequent cardiac pathology illustrating the progressive nature of disease. (C) 2013 Elsevier Inc. All rights reserved.
id UFSP_c419785404f15a2421de07b44e7d1372
oai_identifier_str oai:repositorio.unifesp.br/:11600/36233
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjectsMPSMorquioGALNSLysosomal storage disorderEnduranceRespiratory functionObjectives: the objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects.Methods: MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels.Results: Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean +/- SD height z-scores were -5.6 +/- 3.1 as determined by the CDC growth charts. Mean +/- SD from the 6-minute-walk-test was 212.6 +/- 1522 m, revealing limitations in functional endurance testing, and 30.0 +/- 24.0 stairs/min for the 3-minute-stair-climb test. Respiratory function showed limitations comparable to MPS VI patients; mean +/- SD was 1.2 +/- 0.9 1 based on forced vital capacity and 34.8 +/- 25.5 l/min based on maximum voluntary ventilation. Mean urinary keratan sulfate (uKS) was elevated for all ages, and negatively correlated with age. Higher uKS correlated with greater clinical impairment based on height z-scores, endurance and respiratory function tests. the MPS Health Assessment Questionnaire reveals impairments in mobility and activities of daily living in comparison to an age-matched control population.Conclusions: MPS IVA is a multisystem disorder with a continuum of clinical presentation. All affected individuals experience significant functional limitations and reduced quality of life. Older patients have more severe exercise and respiratory capacity limitations, and more frequent cardiac pathology illustrating the progressive nature of disease. (C) 2013 Elsevier Inc. All rights reserved.Childrens Hosp & Res Ctr Oakland, Oakland, CA USAMC Univ Mainz, Ctr Pediat & Adolescent Med, Mainz, GermanyUniv Fed Rio Grande do Sul, Dept Genet, HCPA, Med Genet Serv, Porto Alegre, RS, BrazilINAGEMP, Porto Alegre, RS, BrazilHop Necker Enfants Malad, Paris, FranceMackay Mem Hosp, Taipei, TaiwanMackay Med Coll, Taipei, TaiwanAz Osped S Gerardo, Monza, ItalyHop Femme Mere Enfant, Lyon, FranceAnn & Robert H Lurie Childrens Hosp, Chicago, IL USANorthwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USABirmingham Childrens Hosp NHS Fdn Trust, Birmingham, W Midlands, EnglandMcGill Univ, Ctr Hlth, Montreal, PQ, CanadaUniversidade Federal de São Paulo, São Paulo, BrazilUniv Manchester, Cent Manchester Univ Hosp, Manchester, Lancs, EnglandHosp Ninos Cordoba, Cordoba, ArgentinaGreat Ormond St Hosp Sick Children, London WC1N 3JH, EnglandUniv Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, NetherlandsUniversidade Federal de São Paulo, São Paulo, BrazilWeb of ScienceBioMarin Pharmaceutical Inc.National Center for Research ResourcesFondazione Pierfranco and Luisa Mariani of MilanoNational Center for Research Resources: 5 M01 RR-01271Elsevier B.V.Childrens Hosp & Res Ctr OaklandMC Univ MainzUniv Fed Rio Grande do SulINAGEMPHop Necker Enfants MaladMackay Mem HospMackay Med CollAz Osped S GerardoHop Femme Mere EnfantAnn & Robert H Lurie Childrens HospNorthwestern UnivBirmingham Childrens Hosp NHS Fdn TrustMcGill UnivUniversidade Federal de São Paulo (UNIFESP)Univ ManchesterHosp Ninos CordobaGreat Ormond St Hosp Sick ChildrenUniv AmsterdamHarmatz, PaulMengel, Karl EugenGiugliani, RobertoValayannopoulos, VassiliLin, Shuan-PeiParini, RossellaGuffon, NathalieBurton, Barbara K.Hendriksz, Christian J.Mitchell, JohnMartins, Ana Maria [UNIFESP]Jones, SimonGuelbert, NorbertoVellodi, AshokHollak, CarlaSlasor, PeterDecker, Celeste2016-01-24T14:31:37Z2016-01-24T14:31:37Z2013-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion54-61application/pdfhttp://dx.doi.org/10.1016/j.ymgme.2013.01.021Molecular Genetics and Metabolism. San Diego: Academic Press Inc Elsevier Science, v. 109, n. 1, p. 54-61, 2013.10.1016/j.ymgme.2013.01.021WOS000318055100010.pdf1096-7192http://repositorio.unifesp.br/handle/11600/36233WOS:000318055100010engMolecular Genetics and Metabolisminfo:eu-repo/semantics/openAccesshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policyreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-07T05:26:18Zoai:repositorio.unifesp.br/:11600/36233Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-07T05:26:18Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
title The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
spellingShingle The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
Harmatz, Paul
MPS
Morquio
GALNS
Lysosomal storage disorder
Endurance
Respiratory function
title_short The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
title_full The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
title_fullStr The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
title_full_unstemmed The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
title_sort The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
author Harmatz, Paul
author_facet Harmatz, Paul
Mengel, Karl Eugen
Giugliani, Roberto
Valayannopoulos, Vassili
Lin, Shuan-Pei
Parini, Rossella
Guffon, Nathalie
Burton, Barbara K.
Hendriksz, Christian J.
Mitchell, John
Martins, Ana Maria [UNIFESP]
Jones, Simon
Guelbert, Norberto
Vellodi, Ashok
Hollak, Carla
Slasor, Peter
Decker, Celeste
author_role author
author2 Mengel, Karl Eugen
Giugliani, Roberto
Valayannopoulos, Vassili
Lin, Shuan-Pei
Parini, Rossella
Guffon, Nathalie
Burton, Barbara K.
Hendriksz, Christian J.
Mitchell, John
Martins, Ana Maria [UNIFESP]
Jones, Simon
Guelbert, Norberto
Vellodi, Ashok
Hollak, Carla
Slasor, Peter
Decker, Celeste
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Childrens Hosp & Res Ctr Oakland
MC Univ Mainz
Univ Fed Rio Grande do Sul
INAGEMP
Hop Necker Enfants Malad
Mackay Mem Hosp
Mackay Med Coll
Az Osped S Gerardo
Hop Femme Mere Enfant
Ann & Robert H Lurie Childrens Hosp
Northwestern Univ
Birmingham Childrens Hosp NHS Fdn Trust
McGill Univ
Universidade Federal de São Paulo (UNIFESP)
Univ Manchester
Hosp Ninos Cordoba
Great Ormond St Hosp Sick Children
Univ Amsterdam
dc.contributor.author.fl_str_mv Harmatz, Paul
Mengel, Karl Eugen
Giugliani, Roberto
Valayannopoulos, Vassili
Lin, Shuan-Pei
Parini, Rossella
Guffon, Nathalie
Burton, Barbara K.
Hendriksz, Christian J.
Mitchell, John
Martins, Ana Maria [UNIFESP]
Jones, Simon
Guelbert, Norberto
Vellodi, Ashok
Hollak, Carla
Slasor, Peter
Decker, Celeste
dc.subject.por.fl_str_mv MPS
Morquio
GALNS
Lysosomal storage disorder
Endurance
Respiratory function
topic MPS
Morquio
GALNS
Lysosomal storage disorder
Endurance
Respiratory function
description Objectives: the objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects.Methods: MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels.Results: Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean +/- SD height z-scores were -5.6 +/- 3.1 as determined by the CDC growth charts. Mean +/- SD from the 6-minute-walk-test was 212.6 +/- 1522 m, revealing limitations in functional endurance testing, and 30.0 +/- 24.0 stairs/min for the 3-minute-stair-climb test. Respiratory function showed limitations comparable to MPS VI patients; mean +/- SD was 1.2 +/- 0.9 1 based on forced vital capacity and 34.8 +/- 25.5 l/min based on maximum voluntary ventilation. Mean urinary keratan sulfate (uKS) was elevated for all ages, and negatively correlated with age. Higher uKS correlated with greater clinical impairment based on height z-scores, endurance and respiratory function tests. the MPS Health Assessment Questionnaire reveals impairments in mobility and activities of daily living in comparison to an age-matched control population.Conclusions: MPS IVA is a multisystem disorder with a continuum of clinical presentation. All affected individuals experience significant functional limitations and reduced quality of life. Older patients have more severe exercise and respiratory capacity limitations, and more frequent cardiac pathology illustrating the progressive nature of disease. (C) 2013 Elsevier Inc. All rights reserved.
publishDate 2013
dc.date.none.fl_str_mv 2013-05-01
2016-01-24T14:31:37Z
2016-01-24T14:31:37Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1016/j.ymgme.2013.01.021
Molecular Genetics and Metabolism. San Diego: Academic Press Inc Elsevier Science, v. 109, n. 1, p. 54-61, 2013.
10.1016/j.ymgme.2013.01.021
WOS000318055100010.pdf
1096-7192
http://repositorio.unifesp.br/handle/11600/36233
WOS:000318055100010
url http://dx.doi.org/10.1016/j.ymgme.2013.01.021
http://repositorio.unifesp.br/handle/11600/36233
identifier_str_mv Molecular Genetics and Metabolism. San Diego: Academic Press Inc Elsevier Science, v. 109, n. 1, p. 54-61, 2013.
10.1016/j.ymgme.2013.01.021
WOS000318055100010.pdf
1096-7192
WOS:000318055100010
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Molecular Genetics and Metabolism
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
eu_rights_str_mv openAccess
rights_invalid_str_mv http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.format.none.fl_str_mv 54-61
application/pdf
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268395256807424